*Sponsored

Up Approx. 12% Early, Low Float (Nasdaq: SHPH) Could Start Drawing Start Drawing Buzz

*Click Here To Get Our Alerts Faster Via SMS*

November 3rd

Dear Reader,

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) continues to move green early Monday, up approx. 12%.

Surging to a high of roughly $4.80, SHPH achieved a run of approx. 61% from last Friday’s close.

And now with the bell in our rearview mirrors, SHPH could really start generating some serious buzz.

A low float of fewer than 1Mn shares could create an environment for heightened volatility potential.

Plus, as I mentioned in my initial report (found below), SHPH had severaloversold leaning technicals after this past Friday’s close.

Could today’s burst be the beginning of a reversal/bounce?

It’s critical to read my initial report below and consider (Nasdaq: SHPH) for your radar this AM.

—–

*Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)*

Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT).

And based on several potential catalysts, (Nasdaq: SHPH) tops my immediate watchlist. Take a look at them:

No. 1 – Could This Tiny Float Create A Scenario For Strong Volatility Potential?

No. 2 – A Binding Term Sheet Moves SHPH That Much Closer To A Game-Changing Acquisition.

No. 3 – A Recent Corporate Update Points To Transformative Company Milestones.

No. 4 – Multiple Technical Indicators Appear Oversold And Possibly Signal A Healthy Reversal Could Be Approaching.

No. 5 – The Company Has Achieved Multiple Partnerships For Cancer Diagnostics And Therapeutics Clinical Trial Development Support.

But more on those in a second…

Pursuing a Cure for Cancer – Shuttle Pharmaceuticals Company Overview

Shuttle Pharmaceuticals is developing novel therapies designed to increase cancer cure rates, prolong patient survival, and improve quality of life.

Improving Outcomes for Cancer Patients

Shuttle Pharmaceuticals develops innovative therapies designed to target cancer cells, protect healthy tissue, and harness the body’s innate immune response. Its mission is to enhance the efficacy of radiation therapy (RT) while minimizing side effects. By leveraging drug discovery and proprietary diagnostic technologies, the company aims to increase cancer cure rates and improve quality of life when its therapies are combined with radiation treatment.

The Next Revolution in Radiation Therapy

Radiation therapy is an effective and proven treatment modality for curing cancers. More than half of all patients diagnosed with cancer in the U.S. receive radiation therapy during their disease course.

Shuttle Pharmaceuticals is developing drugs to sensitize growing cancer cells, making them more susceptible to radiation, activating the DNA damage response pathway to kill malignant cells, and protecting adjacent healthy tissue. Its lead candidate, Ropidoxuridine, is an orally available halogenated pyrimidine with strong radiation-sensitizing properties.

Developing a Novel Portfolio

Using its platform technology to discover novel small molecules that modify the effects of ionizing radiation on cancer cells, Shuttle Pharmaceuticals has built a portfolio of patented selective histone deacetylase (HDAC) inhibitors. Strategic collaborations with academic research institutions have enabled the discovery and exclusive licensing of diagnostic technologies for prostate cancer patient management.

The company’s pipeline includes a Phase II clinical-stage lead product (Ropidoxuridine), three preclinical HDAC inhibitors, and a diagnostic blood test under development for prostate cancer patients.

New Horizons in Diagnostic Technology

Prostate cancers vary in aggressiveness and treatment responses. Shuttle Pharmaceuticals’ predictive biomarker strategy focuses on developing a diagnostic test to assess treatment success risk, guide therapeutic decisions, and inform follow-up management for prostate cancer patients considering elective radiation therapy.

Ropidoxuridine

Ropidoxuridine (IPdR) is Shuttle Pharmaceuticals’ lead radiation sensitizer, designed for use with radiation therapy (RT) to treat glioblastoma, a deadly brain malignancy with no known cure. The FDA has granted the drug Orphan Designation, providing potential marketing exclusivity upon approval.

The oral halogenated pyrimidine incorporates into the DNA of rapidly growing cancer cells, increasing their sensitivity to radiation. Metabolites of IPdR generate reactive uracil free radicals, causing lethal DNA double-strand breaks upon radiation exposure.

Addressing a Critical Need

An estimated 800,000 U.S. patients receive radiation therapy annually, with about 50% undergoing treatment with curative intent. The market opp. for radiation sensitizers includes over 400,000 patients seeking cancer cures each year.

Shuttle Pharmaceuticals is conducting a Phase II trial of Ropidoxuridine for glioblastoma. Results may advance radiation sensitizers to improve cure rates, prolong survival, and enhance quality of life for patients.

HDAC Inhibitors

HDAC inhibitors regulate gene expression by modifying histones and non-histone proteins. Increased HDAC activity condenses chromatin, suppressing tumor suppressor genes, while inhibition opens chromatin, restoring their function. This epigenetic mechanism is a key focus in cancer research.

Driving Next-Gen Cancer Therapy

Shuttle Pharmaceuticals’ R&D focuses on dual-functional molecules that sensitize tumors to radiation, protect healthy tissue, and activate immune responses against irradiated cancer cells. The company holds over 20 HDAC inhibitor patents across the U.S., Canada, and Europe.

Expanding Precision Oncology

Three lead candidates are in development for solid tumors:

• SP-2-225: A Class II (HDAC6)-selective inhibitor enhancing antigen presentation.
• SP-1-303: A Class I inhibitor targeting ER-positive cancers.
• SP-1-161: An ATM gene activator with applications in radiobiology.

Therapeutics Pipeline

Diagnostics

PC-RAD Test is a predictive blood test of therapeutic outcomes to RT for organ-confined prostate cancers.

PSMA-B ligand is a theranostic molecule for diagnosis and therapy of metastatic prostate cancers.

Diagnostics Pipeline

—–

And as I mentioned above, (Nasdaq: SHPH) has several potential catalysts to consider this moment. Take a look:

No. 1 SHPH Potential Catalyst – Could This Tiny Float Create A Scenario For Strong Volatility Potential?

According to the Yahoo Finance website, SHPH has a really tiny low float.

In fact, the website reports this profile to have approximately 987.08k shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

If the company provides positive company news towards the end of 2025, could it provide a near term spark when paired with this volatility potential?

—–

No. 2 SHPH Potential Catalyst – A Binding Term Sheet Moves SHPH That Much Closer To A Game-Changing Acquisition.

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Rockville, Maryland–(Newsfile Corp. – October 21, 2025) – Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) (“Shuttle” or the “Company”) today announced that it has entered into a binding term sheet with 1542770 BC Ltd. (“Molecule”), a Canadian artificial intelligence company specializing in molecular discovery and drug development technologies.

Under the terms of the agreement, Shuttle or one of its affiliates will acquire substantially all of Molecule’s assets and liabilities for a total purchase price of $10Mn, payable in a combination of cash and shares of Shuttle common st-ock. The exact mix of cash and equity will be determined by Shuttle at its sole discretion and will be paid over time, subject to the achievement of certain performance milestones.

The parties intend to finalize one or more definitive agreements to complete the transaction, which will include customary representations, warranties, and closing conditions. The closing of the acquisition will be subject to, among other things, satisfactory completion of mutual due diligence and the execution of the final transaction documents.

“This proposed acquisition represents an important strategic step toward expanding Shuttle’s technological capabilities and advancing our mission of developing precision radiotherapy solutions,” said Chris Cooper, Chief Executive Officer of Shuttle Pharmaceuticals. “Molecule’s AI platform offers cutting-edge tools for molecular modeling and predictive analytics that can enhance our drug discovery and development pipeline.”

Read the full article here.

—–

No. 3 SHPH Potential Catalyst – A Recent Corporate Update Points To Transformative Company Milestones.

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

GAITHERSBURG, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update.

Recent Activities:

• Patient enrollment in the Company’s Phase 2 clinical trial of Ropidoxuridine for treatment of patients with glioblastoma reached 63% in the initial randomized portion of the trial.

• 72% of the enrolled patients have completed all seven cycles.

• Ropidoxuridine is being reported by treatment sites as well tolerated.

• Ended the quarter with $4.8Mn in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited in-vest-or for aggregate gross proceeds of $4.25Mn in June 2025.

• Completed a reverse st-ock split in June 2025 as part of strategic Nasdaq compliance initiative.

• Appointed George Scorsis as the Chairman of the Board of Directors and appointed Christopher Cooper, our current Interim Chief Executive Officer to our Board of Directors. Mr. Scorsis has over 25 years of experience leading companies in highly regulated industries to rapid growth. Mr. Cooper has over 27 years of management and finance experience.

“We are encouraged by the progress in our Phase 2 clinical trial of Ropidoxuridine for glioblastoma, with 63% enrollment having recently been achieved. Importantly, 72% of enrolled patients have completed all seven cycles with treatment reported as being well-tolerated,” commented Shuttle Pharma’s interim Chief Executive Officer, Chris Cooper. “We are working closely with our primary third-party CRO, Theradex Systems, to continue execution of the clinical trial in combination with leading cancer centers across the U.S. Our goal continues to remain completion of enrollment later this year, with follow-up and data readouts anticipated in 2026.”

…

Read the full article here.

—–

No. 4 SHPH Potential Catalyst – Multiple Technical Indicators Appear Oversold And Possibly Signal A Healthy Reversal Could Be Approaching.

At 4:00PM EST Friday, Barchart was reporting SHPH to have several oversold leaning technical indicators.

These technicals could be signaling a healthy reversal is approaching in the near term.

Here’s the definition of a “reversal” from Investopedia:

“A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart.”

Here’s the technicals to pay close attention to (as of 4:00PM EST Friday):

• 9-Day Relative Strength Index: 28.93%
• 14-Day Relative Strength Index: 35.14%

When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.

• 14-Day Raw Stochastic %D: 5.16%

As the Raw Stochastic nears the 10% range and lower it may also be viewed as oversold and undervalued.

Keep an eye on these technicals closely.

—–

No. 5 SHPH Potential Catalyst – The Company Has Achieved Multiple Partnerships For Cancer Diagnostics And Therapeutics Clinical Trial Development Support.

Shuttle Pharmaceuticals Holdings, Inc. maintains strategic agreements and contracts with academic institutions to access intellectual property, core facilities, and contracting relationships essential to its programs.

University of California, San Francisco (UCSF)

Shuttle entered a sponsored research agreement with UCSF to advance pre-clinical development of Shuttle Diagnostics, Inc.’s PSMA ligand as a potential theranostic molecule, led by principal investigator Robert Flavell, M.D., Ph.D.. The work aims to develop radiosynthetic methods for producing the [18F]FPA-ACUPA probe, investigate cellular binding in prostate cancer cell lines, and assess diagnostic potential across prostate cancer phenotypes; Shuttle holds an exclusive license to PSMA-B intellectual property and has filed a U.S. patent application.

Georgetown University

Georgetown University’s Lombardi Comprehensive Cancer Center supports discovery and development of cancer diagnostics and therapeutics, with Shuttle subcontracting SBIR-funded clinical work to establish cancer cell lines from African-American patients and develop predictive biomarkers for radiation late-effects sensitivity.

Brown University

Shuttle received an NIH SBIR contract for a Phase I clinical trial with Brown University at Lifespan/Rhode Island Hospital to determine the maximum tolerated dose in advanced gastrointestinal cancers, with NCI approving the protocol and providing drug and clinical data management support. The completed Phase I trial supports advancing Ropidoxuridine to Phase II trials in brain tumors, sarcomas, and other tumors.

University of Virginia

The University of Virginia, which developed “Atomic Radiation” intellectual property, collaborates with Shuttle scientists on sensitizers for use with proton radiation therapy.

George Washington Cancer Center

Collaborations between the Villagra lab at George Washington University and Shuttle’s lab led to an October 2020 AACR presentation on “Immune-mediated Tumor Growth Inhibition by Selective HDAC6 Inhibitor SP-2-225,” with Dr. Villagra serving as a Shuttle scientific advisor since 2017. A material transfer agreement supports testing HDAC inhibitor effects in immune model systems.

TCG GreenChem

TCG GreenChem Inc., part of the TCG Group with presence in the United States, India, and Japan, is a CRAMS company affiliated with TCG Lifesciences Pvt. Ltd. and joined Shuttle’s leadership team in 2020 to manufacture drug product for proposed clinical trials. TCG GreenChem has also been engaged to manufacture Ropidoxuridine and perform process R&D and optimization to support Shuttle’s clinical programs.

—–

(Nasdaq: SHPH) Recap – These Potential Catalysts Could Provide A Breakout Spark

No. 1 – Could This Tiny Float Create A Scenario For Strong Volatility Potential?

No. 2 – A Binding Term Sheet Moves SHPH That Much Closer To A Game-Changing Acquisition.

No. 3 – A Recent Corporate Update Points To Transformative Company Milestones.

No. 4 – Multiple Technical Indicators Appear Oversold And Possibly Signal A Healthy Reversal Could Be Approaching.

No. 5 – The Company Has Achieved Multiple Partnerships For Cancer Diagnostics And Therapeutics Clinical Trial Development Support.

—–

Now underway: coverage is initiated on Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH).

As soon as updates are available, I’ll get them out the door to you. Talk shortly.

Sincerely,

FierceAnalyst | Jaks Swift

Editorial Writer

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (“FI”) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/02/2025 and ending on 11/03/2025 to publicly disseminate information about (SHPH:US) via digital communications. Under this agreement, SWN Media LLC has been paid twenty thousand USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid thirty seven thousand five hundred USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither SWN Media LLC, TD Media LLC and their member own shares of (SHPH:US).

Please see important disclosure information here: https://fierceinvestor.com/disclosure/shph-7e6wx/#details